Citrobacter Diversus
Mostrando 13-24 de 53 artigos, teses e dissertações.
-
13. Citrobacter diversus isolated from clinical material.
Forty-seven strains of Citrobacter diversus were isolated during a 12-month period from clinical material obtained from patients in a general hospital in Israel. The majority of cultures (38) were recovered from urine and wound discharges. There was one case of septicemia. The biochemical reactions of all cultures were typical for this species, except one th
-
14. Characterization of blaTEM-3 and blaSHV-4 beta-lactamase-encoding genes in Citrobacter diversus.
-
15. Development of resistance to cephalosporins in clinical strains of Citrobacter spp.
The predominant beta-lactam antibiogram of Citrobacter freundii resembles that of Enterobacter cloacae in demonstrating resistance to cephalothin and cefoxitin with susceptibility to the newer cephalosporins. Four representative strains of C. freundii were reversibly induced to high-level beta-lactamase production by cefoxitin, and mutants with stable, high-
-
16. Analysis of relationships among isolates of Citrobacter diversus by using DNA fingerprints generated by repetitive sequence-based primers in the polymerase chain reaction.
Oligonucleotide probes which match consensus sequences of the repetitive extragenic palindromic (REP) element hybridize to genomic DNA of diverse bacterial species. Primers based on the REP sequence generate complex band patterns with genomic DNA in the polymerase chain reaction (PCR), a technique named REP-PCR. We used REP-PCR with genomic DNA to fingerprin
-
17. Ability of commercial identification systems to identify newly recognized species of Citrobacter.
The genus Citrobacter was recently determined to contain 11 genetically distinct species. In addition, the International Committee on Systematic Bacteriology no longer recognizes C. diversus and has, instead, validated the name C. koseri in its place. The 11 species are C. freundii, C. koseri, C. amalonaticus, C. farmeri, C. youngae, C. braakii, C. werkmanii
-
18. Evaluation of tyrosine medium for the identification of Enterobacteriaceae.
Use of the tyrosine medium in the identification of members of the family Enterobacteriaceae form the basis of this paper. Six hundred and twenty-three strains were tested for their property of tyrosine degradation. Three hundred and seventy-two strains were positive in 24 h and an additional eight strains were positive in 48 to 72 h. These positive strains
-
19. Screening of bacterial isolates for mannose-specific lectin activity by agglutination of yeasts.
A total of 393 clinical bacterial isolates were tested for their ability to agglutinate yeast cells of either Saccharomyces cerevisiae or Candida albicans. A positive agglutination of yeasts that could be prevented by methyl alpha-D-mannoside was taken as an indication for the possible presence of a mannose-specific lectin (carbohydrate-binding protein) on t
-
20. beta-Lactamase inhibitory activity of iodopenicillanate and bromopenicillanate.
Iodopenicillanate and bromopenicillanate were shown to be effective inhibitors of a variety of beta-lactamases. Staphylococcus aureus isolates were synergistically inhibited by iodopenicillanate and bromopenicillanate combined with ampicillin. Methicillin-resistant S. aureus was not synergistically inhibited. Escherichia coli which possessed TEM beta-lactama
-
21. Comparison of In Vitro Activity of Cephalexin, Cephradine, and Cefaclor
Inhibitory activity of cephalexin, cephradine, and cefaclor was compared by the WHO-ICS agar dilution technique. Cefaclor was substantially more active against staphylococci, streptococci, gonococci, meningococci, Haemophilus, Escherichia coli, Klebsiella pneumoniae, Citrobacter diversus, Proteus mirabilis, salmonellae, and shigellae than was cephalexin, whi
-
22. Novel Class A β-Lactamase Sed-1 from Citrobacter sedlakii: Genetic Diversity of β-Lactamases within the Citrobacter Genus
Citrobacter sedlakii 2596, a clinical strain resistant to aminopenicillins, carboxypenicillins, and early cephalosporins such as cephalothin, but remaining susceptible to acylureidopenicillins, carbapenems, and later cephalosporins such as cefotaxime, was isolated from the bile of a patient treated with β-lactam and quinolone antibiotics. The isolate produc
American Society for Microbiology.
-
23. In vitro activity of sparfloxacin (CI-978; AT-4140) against clinical isolates from cancer patients.
The in vitro activity of sparfloxacin, a new quinolone, was compared with those of ciprofloxacin and fleroxacin against gram-positive and gram-negative bacteria, greater than 90% of which were isolated from blood culture specimens of cancer patients. Sparfloxacin was extremely active against Acinetobacter species, Aeromonas hydrophila, Citrobacter diversus,
-
24. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.
The in vitro activities of ticarcillin, piperacillin, clavulanic acid, tazobactam, ticarcillin-clavulanate, and piperacillin-tazobactam against 819 bacterial isolates were compared. The two beta-lactamase inhibitors, clavulanic acid and tazobactam, had little useful antibacterial activity but enhanced the activities of the penicillins against beta-lactamase-